Biohaven Ltd. (BHVN): Total Liabilities
$399.38M
As of 2025-12-31
$358.52M
As of 2026-06-30
+48.1%
3-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $399.38M | +108.4% | 2026-03-02, Balance as of period end |
| 2024-12-31 | $191.67M | +124.9% | 2026-03-02, Balance as of period end |
| 2023-12-31 | $85.24M | -30.7% | 2025-03-03, Balance as of period end |
| 2022-12-31 | $123.01M | +159.7% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $47.37M | n/a | 2023-03-23, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Biohaven Ltd. (BHVN) | 2025-12-31 | $399.38M | +108.4% |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | 2025-12-31 | $37.28M | +90.4% |
| BGM Group Ltd. (BGM) | 2025-09-30 | $41.92M | +370.4% |
| Arcutis Biotherapeutics, Inc. (ARQT) | 2025-12-31 | $243.49M | +27.3% |
| Bicara Therapeutics Inc. (BCAX) | 2025-12-31 | $29.54M | +63.0% |
| Enliven Therapeutics, Inc. (ELVN) | 2025-12-31 | $16.57M | +4.1% |
| MapLight Therapeutics, Inc. (MPLT) | 2025-12-31 | $21.14M | -2.7% |
| MoonLake Immunotherapeutics (MLTX) | 2025-12-31 | $119.95M | +388.8% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $210.17M | -7.7% |
Compare BHVN, BBOT, BGM, ARQT side by side · Screen every company in Pharmaceutical Preparations ↗